These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease--a possible target for infliximab treatment. Agnholt J, Kelsen J, Brandsborg B, Jakobsen NO, Dahlerup JF. Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):649-55. PubMed ID: 15201577 [Abstract] [Full Text] [Related]
3. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Ricevuti L, Cifone MG, Corazza GR. Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579 [Abstract] [Full Text] [Related]
5. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Van den Brande JM, Koehler TC, Zelinkova Z, Bennink RJ, te Velde AA, ten Cate FJ, van Deventer SJ, Peppelenbosch MP, Hommes DW. Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252 [Abstract] [Full Text] [Related]
9. Use of a 99mTc labeled anti-TNFalpha monoclonal antibody in Crohn's disease: in vitro and in vivo studies. D'Alessandria C, Malviya G, Viscido A, Aratari A, Maccioni F, Amato A, Scopinaro F, Caprilli R, Signore A. Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):334-42. PubMed ID: 17464276 [Abstract] [Full Text] [Related]
13. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, Targan SR. J Immunol; 1997 Dec 15; 159(12):6276-82. PubMed ID: 9550432 [Abstract] [Full Text] [Related]
14. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Magro F, Portela F. BioDrugs; 2010 Dec 14; 24 Suppl 1():3-14. PubMed ID: 21175228 [Abstract] [Full Text] [Related]
16. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S. Dig Liver Dis; 2004 May 14; 36(5):342-7. PubMed ID: 15191204 [Abstract] [Full Text] [Related]
17. Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease. van Balkom BP, Schoon EJ, Stockbrügger RW, Wolters FL, van Hogezand RA, van Deventer SJ, Oldenburg B, van Dullemen HM, Russel MG. Aliment Pharmacol Ther; 2002 Jun 14; 16(6):1101-7. PubMed ID: 12030951 [Abstract] [Full Text] [Related]
19. The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn's disease - an immunohistochemical study. Eder P, Lykowska-Szuber L, Krela-Kazmierczak I, Stawczyk-Eder K, Zabel M, Linke K. J Crohns Colitis; 2013 Oct 14; 7(9):706-16. PubMed ID: 23021876 [Abstract] [Full Text] [Related]
20. Anti-TNF antibodies do not induce the apoptosis of lamina propria mononuclear cells in uninflamed intestinal tissue in patients with Crohn's disease. Eder P, Lykowska-Szuber L, Krela-Kazmierczak I, Stawczyk-Eder K, Sterzynska K, Iwanik K, Majewski P, Zabel M, Linke K. Folia Histochem Cytobiol; 2013 Oct 14; 51(3):239-43. PubMed ID: 24203631 [Abstract] [Full Text] [Related] Page: [Next] [New Search]